Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Design Therapeutics, Inc. (DSGN)
Company Research
Source: Yahoo! Finance
IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today provided an update on the progress of its platform of GeneTAC™ portfolio assets and reported fourth quarter and full year 2023 financial results. “At Design, our vision is to develop a portfolio of first or best-in-class small molecules
Show less
Read more
Impact Snapshot
Event Time:
DSGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSGN alerts
High impacting Design Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DSGN
News
- Independent Director of Design Therapeutics Picks Up 88% More Stock [Yahoo! Finance]Yahoo! Finance
- Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics, Inc. (NASDAQ: DSGN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.MarketBeat
- Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics, Inc. (NASDAQ: DSGN) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
DSGN
Earnings
- 3/19/24 - Beat
DSGN
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- DSGN's page on the SEC website